Management of Excessive Secretions in Palliative Care

Anticholinergic Medication Options

Glycopyrrolate does not effectively cross the blood-brain barrier, making it less likely to cause sedation, drowsiness, or delirium compared to scopolamine, and is effective for reducing excessive secretions associated with dyspnea 1, 3
The National Comprehensive Cancer Network recommends glycopyrrolate as a first-line option for managing excessive secretions, administered intravenously or subcutaneously at a dose of 0.2-0.4 mg every 4 hours as needed 1, 4
Glycopyrrolate may produce peripheral anticholinergic side effects, such as dry mouth and urinary retention, but with minimal central nervous system effects 1
Atropine can be used as an alternative, administered as 1% ophthalmic solution, 1-2 drops sublingually every 4 hours as needed 1, 4
Hyoscyamine is another anticholinergic option but also crosses the blood-brain barrier and may cause sedation 3
Scopolamine crosses the blood-brain barrier readily, causing significant central nervous system effects, including drowsiness, disorientation, confusion, and potential delirium 1, 3

The American College of Physicians recommends considering glycopyrrolate as the first-line option for patients where sedation is a concern, particularly for elderly patients who are more sensitive to CNS effects 4
Alternative options, such as atropine or scopolamine, can be considered if glycopyrrolate is unavailable or ineffective 1, 3

The goal of managing secretions in palliative care is to reduce distressing symptoms while minimizing adverse effects that could impact quality of life 1, 3
Anticholinergic medications should be used when secretions are causing distress, such as noisy breathing or dyspnea 3